Janus Henderson Group PLC Acquires 756,032 Shares of Biohaven Ltd. (NYSE:BHVN)

Janus Henderson Group PLC lifted its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 12.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,982,425 shares of the company's stock after buying an additional 756,032 shares during the period. Janus Henderson Group PLC owned approximately 6.91% of Biohaven worth $260,735,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Spire Wealth Management bought a new stake in Biohaven during the fourth quarter worth $56,000. Amalgamated Bank lifted its stake in Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after purchasing an additional 527 shares during the last quarter. US Bancorp DE lifted its stake in Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock worth $111,000 after purchasing an additional 798 shares during the last quarter. Quarry LP bought a new position in shares of Biohaven in the 4th quarter valued at $112,000. Finally, Elkhorn Partners Limited Partnership lifted its stake in shares of Biohaven by 50.0% in the 4th quarter. Elkhorn Partners Limited Partnership now owns 3,300 shares of the company's stock valued at $123,000 after acquiring an additional 1,100 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors.

Biohaven Stock Down 19.6%

Biohaven stock traded down $3.85 during trading hours on Thursday, reaching $15.81. 7,703,411 shares of the company's stock were exchanged, compared to its average volume of 1,198,005. The firm's 50 day simple moving average is $22.81 and its 200 day simple moving average is $34.80. Biohaven Ltd. has a twelve month low of $15.12 and a twelve month high of $55.70. The firm has a market capitalization of $1.61 billion, a PE ratio of -1.69 and a beta of 1.18.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.50). Analysts anticipate that Biohaven Ltd. will post -8.9 EPS for the current year.

Wall Street Analysts Forecast Growth

BHVN has been the subject of a number of research reports. Royal Bank of Canada dropped their price target on Biohaven from $61.00 to $54.00 and set an "outperform" rating for the company in a research note on Tuesday. Cantor Fitzgerald upgraded Biohaven to a "strong-buy" rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft set a $60.00 price target on Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. Morgan Stanley dropped their price target on Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Finally, Robert W. Baird decreased their price objective on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a report on Monday, April 28th. Thirteen analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $62.00.

Insider Activity

In other news, Director John W. Childs bought 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The stock was bought at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the purchase, the director now directly owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This represents a 1.43% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.00% of the stock is currently owned by company insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.